Nantkwest, Inc.

NASDAQ: NKHealthcare / Biotechnology / USA
1.10-0.0500-4.35%Vol 303 8391Y Perf -60.44%
Jun 20th, 2019 16:00
BID1.09 ASK1.10
Open1.19 Previous Close1.15
Pre-Market- After-Trading1.10
 - -%  - -%
Target Price
1.25 
Analyst Rating
Moderate Sell 4.00
Potencial %
13.64 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/-100 
Growth Ranking
     36.82
Insiders Shares Cnt. % 3/6/12M
-/-/-100 
Income Ranking
 —    -
Market Cap (mil)109 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
5.15 
Earnings Date
14th Aug 2019

Today's Price Range

1.081.19

52wk Range

0.93004.23

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Month
9.52%
3 Months
-12.88%
6 Months
1.77%
1 Year
-60.44%
3 Years
-82.33%
5 Years
-

Name / TickerPriceChg.Chg.%
NK1.10-0.0500-4.35
AAPL199.461.59000.80
GOOG1 111.429.09000.82
MSFT136.951.26000.93
XOM76.611.29001.71
WFC45.860.21000.46
JNJ142.211.76001.25
FB189.532.05001.09
GE10.630.29002.80
JPM110.190.28000.25
Earnings HistoryEstimateReportedSurprise %
Q01 2019-0.23-0.224.35
Q03 2018-0.37-0.3018.92
Q01 2018-0.34-0.35-2.94
Q04 2017--0.31-
Q02 2017-0.32-0.299.38
Q01 2017-0.39-0.3023.08
Q02 2016-0.35-0.41-17.14
Q01 2016-0.24-0.38-58.33
Earnings Per EndEstimateRevision %Trend
6/2019 QR-0.2510.71Positive
9/2019 QR-0.2610.34Positive
12/2019 FY-0.8221.90Positive
12/2020 FY-0.380.00-
Next Report Date14th Aug 2019
Estimated EPS Next Report-0.25
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume303 839
Shares Outstanding (in ths.)98 674
Trades Count565
Dollar Volume299 009
Avg. Volume438 402
Avg. Weekly Volume267 024
Avg. Monthly Volume514 311
Avg. Quarterly Volume572 657
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (50.00 %)
2 (100.00 %)
3 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (50.00 %)
0 (0.00 %)
0 (0.00 %)
RatingModerate Sell
4.00
Hold
3.00
Hold
3.00

Nantkwest, Inc.

NantKwest Inc is a United States-based firm functioning in the healthcare sector. It is focused on providing immunotherapeutic agents, especially natural killer cells to treat cancer, infectious and inflammatory diseases. Natural Killer (NK) cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. The company's drug candidates such as activated NK cells, high-affinity NKs and target activated NK's address virally-induced cancers, viral, fungal and bacterial infections as well as critical diseases such as Ebola. Its pipeline product includes taNK, haNK, and aNK. Most of NatWest's sales are concentrated in the United States region although it has a reasonable market in Europe and other Non-U.S. territories.

CEO: Patrick Soon-Shiong

Teplephone: +1 858 633-0300

Address: 3530 John Hopkins Court, San Diego 92121, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

78%22%

Bearish Bullish

53%47%

Bearish Bullish

78%22%

News